ProlacriaTreatment for Dry Eye
Inspire Announces Receipt of FDA Approvable Letter for Diquafosol
DURHAM, N.C., December 2, 2005 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the U.S. Food and Drug Administration (FDA) has issued a second approvable letter for diquafosol tetrasodium ophthalmic solution.
The FDA approvable letter included the following statement: "The submitted clinical studies fail to demonstrate adequate replication of results for the efficacy endpoints and therefore are insufficient to establish efficacy. Based on our review of the submitted data, consistent findings of corneal clearing need to be demonstrated to support the efficacy of the drug product."
Christy L. Shaffer, Ph.D., President and CEO of Inspire, stated, "In the approvable letter, the FDA strongly encouraged us to meet with them to discuss how best to move forward with the application. We intend to request this meeting in the near future. In addition, our Joint Development Committee with Allergan will be meeting next week to discuss strategies for the program. We plan to provide an additional update on this program following the FDA meeting and discussions with Allergan."
Dr. Scott Whitcup, Executive Vice President, Research & Development of Allergan, Inc., commented, "We are committed to supporting Inspire's effort to secure approval for diquafosol. Though the development of pharmaceuticals to treat dry eye disease is challenging, we still believe that diquafosol could potentially provide a valuable addition to the spectrum of treatments available to patients suffering from dry eye."
Posted: December 2005
- Inspire Continues Discussions with FDA on Dry Eye Program - October 5, 2006
- Inspire Announces Outcome of FDA Meeting on Dry Eye Program - March 28, 2006
- Inspire Submits Amendment to New Drug Application for Diquafosol for the Treatment of Dry Eye - June 1, 2005
- Inspire Pharmaceuticals Announces Outcome of Meeting with the FDA on Diquafosol - January 30, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.